Drug Profile
Research programme: biodegradable gold nanoparticles - PolyAurum
Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer PolyAurum
- Class Antineoplastics; Diagnostic agents; Imaging agents; Metals; Radiation-sensitising agents
- Mechanism of Action Diagnostic imaging enhancers; Image enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Unspecified
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for research development in Cancer(Adjuvant therapy) in USA (Parenteral, Injection)
- 28 Jun 2020 No recent reports of development identified for research development in Unspecified(Diagnosis) in USA (Parenteral, Injection)